Literature DB >> 22367595

Endovascular therapy for vasculogenic erectile dysfunction.

Jason H Rogers1, Krishna J Rocha-Singh.   

Abstract

OPINION STATEMENT: Erectile dysfunction (ED) is an important clinical condition that affects a significant proportion of men. Although there are many etiologies for ED, many cases have a vascular basis that is related to inadequate arterial inflow, veno-occlusive dysfunction, or abnormalities in smooth muscle (cavernosal tissue) relaxation. These vascular abnormalities can exist in isolation or combination. Since the advent of phosphodiesterase-5 inhibitor (PDE5i) therapy, the initial management of ED in most cases consists of a brief medical evaluation followed by a trial of PDE5i therapy. However, up to 50% of men have an inadequate response to PDE5i therapy and discontinue therapy. Subsequent therapies for ED are increasingly invasive, including penile injection of vasodilators, vacuum pumps, and penile implants. With increased awareness of ED among clinicians and the growing mechanistic link between ED and atherosclerotic vascular disease, there has been renewed interest in the diagnosis and management of arteriogenic ED. Prior reports in the 1980s described the existence of arterial inflow lesions in patients with ED, and there are a modest number of reports describing the feasibility of revascularization with balloon angioplasty. Despite initial clinical success, enthusiasm for this technique waned, presumably because ED frequently recurred due to restenosis and lack of small vessel endovascular therapies. Recent investigation and the availability of newer tools such as drug-eluting stents have renewed interest in this field. Although conceptually attractive, endovascular therapy for ED presents significant challenges related to unanswered questions such as the prevalence and appropriate diagnostic evaluation of arteriogenic ED, and the safety and feasibility of stent-based therapies in this population. In addition, the evaluation, management, and follow-up of patients with vascular ED require a multi-disciplinary team with specialists in urology, sexual medicine, and vascular medicine. Despite these challenges, the potential for endovascular treatment of these patients remains one of the most exciting areas of investigation in vascular medicine.

Entities:  

Year:  2012        PMID: 22367595     DOI: 10.1007/s11936-012-0171-z

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  43 in total

Review 1.  The worldwide prevalence and epidemiology of erectile dysfunction.

Authors:  J B McKinlay
Journal:  Int J Impot Res       Date:  2000-10       Impact factor: 2.896

2.  Erectile dysfunction and subsequent cardiovascular disease.

Authors:  Ian M Thompson; Catherine M Tangen; Phyllis J Goodman; Jeffrey L Probstfield; Carol M Moinpour; Charles A Coltman
Journal:  JAMA       Date:  2005-12-21       Impact factor: 56.272

3.  Impotence due to the pelvic steal syndrome: treatment by iliac transluminal angioplasty.

Authors:  B Goldwasser; C C Carson; S D Braun; R L McCann
Journal:  J Urol       Date:  1985-05       Impact factor: 7.450

4.  Evaluation of arteriogenic impotence with intracorporeal injection of papaverine and the duplex ultrasound scanner.

Authors:  T F Lue; H Hricak; K W Marich; E A Tanagho
Journal:  Semin Urol       Date:  1985-02

5.  Investigation of impotence by internal pudendal angiography: experience with 73 cases.

Authors:  R R Gray; A G Keresteci; E L St Louis; H Grosman; M A Jewett; J T Rankin; J L Provan
Journal:  Radiology       Date:  1982-09       Impact factor: 11.105

6.  Cigarette smoking: an independent risk factor for atherosclerosis in the hypogastric-cavernous arterial bed of men with arteriogenic impotence.

Authors:  M P Rosen; A J Greenfield; T G Walker; P Grant; J Dubrow; M A Bettmann; L E Fried; I Goldstein
Journal:  J Urol       Date:  1991-04       Impact factor: 7.450

7.  The cost-effectiveness of sildenafil.

Authors:  K J Smith; M S Roberts
Journal:  Ann Intern Med       Date:  2000-06-20       Impact factor: 25.391

8.  Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease.

Authors:  Francesco Montorsi; Alberto Briganti; Andrea Salonia; Patrizio Rigatti; Alberto Margonato; Andrea Macchi; Stefano Galli; Paolo M Ravagnani; Piero Montorsi
Journal:  Eur Urol       Date:  2003-09       Impact factor: 20.096

9.  Coronary artery risk factors in patients with erectile dysfunction.

Authors:  Ahmed I El-Sakka; Ayman M Morsy; Bassam I Fagih; Ahmed H Nassar
Journal:  J Urol       Date:  2004-07       Impact factor: 7.450

10.  Early experience with balloon angioplasty of internal iliac arteries for vasculogenic impotence.

Authors:  P Angelini; S Fighali
Journal:  Cathet Cardiovasc Diagn       Date:  1987 Mar-Apr
View more
  4 in total

Review 1.  Endovascular treatment of vasculogenic erectile dysfunction.

Authors:  Edward D Kim; Ryan C Owen; Gregory S White; Osama O Elkelany; Cyrus D Rahnema
Journal:  Asian J Androl       Date:  2015 Jan-Feb       Impact factor: 3.285

2.  Phase I and registry study of autologous bone marrow concentrate evaluated in PDE5 inhibitor refractory erectile dysfunction.

Authors:  Mark Bieri; Elias Said; Gabrielle Antonini; Donald Dickerson; Jorge Tuma; Courtney E Bartlett; Amit N Patel; Alexander Gershman
Journal:  J Transl Med       Date:  2020-01-14       Impact factor: 5.531

Review 3.  Sexual dysfunction in 2013: Advances in epidemiology, diagnosis and treatment.

Authors:  King Chien Joe Lee; Nader Fahmy; Gerald B Brock
Journal:  Arab J Urol       Date:  2013-07-23

4.  Erectile dysfunction after urethroplasty.

Authors:  Adam Kałużny; Jakub Krukowski; Marcin Matuszewski
Journal:  Cent European J Urol       Date:  2019-12-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.